Gapping up
In reaction to strong earnings/guidance:
- AMRN +8.7%, SMPL +4.9%
Other news:
- CYAD +10.8% (announces strategic updates to the autologous r/r AML and MDS program; to hold call tomorrow at 8 a.m. EDT)
- SRC +3.2% (to join S&P MidCap 400)
- IOVA +3.1% (provided an update on the regulatory path for LN-145 in advanced cervical cancer)
- TEVA +0.8% (reports results showing improvement in disability and quality of life from the Phase IIIb FOCUS study of Fremanezumab)
Analyst comments:
- DOVA +4.8% (upgraded to Outperform from In-line at Evercore ISI)
- CARS +3% (upgraded to Buy from Neutral at Citigroup)
- RVLV +2.9% (initiated with an Overweight at Morgan Stanley, among others)
- VERU +2.8% (initiated with Overweight at Cantor Fitzgerald)
- HMSY +1.6% (upgraded to Buy at Chardan Capital Markets)
- MPW +1.4% (upgraded to Buy from Hold at SunTrust)
- CNP +1.2% (added to Conviction Buy List at Goldman)
- LSTR +0.6% (upgraded to Mkt Perform from Underperform at Raymond James)